Published: Sun, January 14, 2018
Business | By Tara Barton

Sucampo Pharmaceuticals (NASDAQ:SCMP) Stock Rating Reaffirmed by Leerink Swann

On January 9, 2018, NASDAQ:SCMP shares closed at $18.50 per share. The company's outstanding shares are 46.9 Million.

Sucampo Pharmaceuticals, Inc.'s Average Earnings Estimate for the current quarter is $0.29, according to consensus of 3 analysts.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SCMP. SG Americas Securities LLC lifted its position in shares of Sucampo Pharmaceuticals by 5.6% in the second quarter. Advisor Group Inc. now owns 20,475 shares of the biopharmaceutical company's stock worth $242,000 after purchasing an additional 6,361 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Sucampo Pharmaceuticals in the second quarter valued at $117,000. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company's stock worth $4,842,000 after purchasing an additional 368,090 shares during the last quarter. Institutional investors own 65.29% of the company's stock. Employees Retirement Systems Of Ohio has invested 0% in Sucampo Pharmaceuticals, Inc. Sucampo Pharmaceuticals, Inc. (SCMP)'s value Change from Open was at 1.94% with a Gap of 0.00%. The company has market cap of $862.55 million. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. Finally, SGYP's beta of 1.24 indicates that the stock has an above average level of market risk. Mizuho maintained the shares of SCMP in report on Wednesday, January 3 with "Hold" rating. They expect $-0.90 EPS, up 47.37% or $0.81 from last year's $-1.71 per share. The company had revenue of $61.27 million during the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. The company's quarterly revenue was up 73.4% on a year-over-year basis.

Sucampo Pharmaceuticals, Inc. (SCMP) have shown a high EPS growth of 24.80% in the last 5 years and has earnings decline of -42.20% yoy.

A number of other research analysts also recently issued reports on SCMP. They now have a $18.00 price target on the biopharmaceutical company's stock, up from their previous price target of $14.00. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Tuesday, October 3rd.

DISH Network (NASDAQ:DISH) Receiving Somewhat Favorable Media Coverage, Report Finds
The rating was maintained by Keefe Bruyette & Woods with "Hold" on Wednesday, January 10. (NYSE:EVR) rating on Thursday, July 27. DISH Network Corporation ( DISH ) has 0 billion shares outstanding now , 99.44% of which belong to institutional investors.

Maxim Group downgraded shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) to a hold rating in a research report report published on Monday, January 1st. On Tuesday, November 15 the stock rating was maintained by Maxim Group with "Buy".

Among 13 analysts covering Sucampo Pharma (NASDAQ:SCMP), 5 have Buy rating, 0 Sell and 8 Hold. Sucampo Pharmaceuticals now has a consensus rating of "Buy" and an average price target of $17.33.

In related news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction on Thursday, December 7th. To cut down amount of noise on price chart, shares of firm has 20 days moving average price of 6.66% from last close price of 18.55 and act as support or resistance of price limit. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

ILLEGAL ACTIVITY WARNING: This story was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. The correct version of this article can be accessed at

A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland. The Company's product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders.

Like this: